GLP1R and type 2 diabetes mellitus: In our study, only a minority of patients with pre-transplant T2DM received DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT-2 inhibitors, as the majority of patients with oral anti-diabetic medications were still on metformin.